Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 2,560 at Berenberg Bank

Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its price objective boosted by investment analysts at Berenberg Bank from GBX 2,400 ($29.74) to GBX 2,560 ($31.73) in a report issued on Wednesday, Marketbeat reports. The firm currently has a "buy" rating on the stock. Berenberg Bank's target price points to a potential upside of 11.69% from the stock's current price.

Hikma Pharmaceuticals Price Performance

HIK traded up GBX 12 ($0.15) during midday trading on Wednesday, hitting GBX 2,292 ($28.41). 1,187,295 shares of the company traded hands, compared to its average volume of 1,234,845. The company has a market capitalization of £5.09 billion, a price-to-earnings ratio of 3,526.15, a PEG ratio of 2.38 and a beta of 0.41. The business has a 50 day simple moving average of GBX 2,010.67 and a two-hundred day simple moving average of GBX 1,950.92. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.48. Hikma Pharmaceuticals has a 52-week low of GBX 1,750 ($21.69) and a 52-week high of GBX 2,296 ($28.45).

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.